Benzinga | Nov 4, 2020 01:08PM EST

GlycoMimetics Highlights 3 Abstracts Accepted For Oral Presentations, 2 Abstracts For Poster Presentations At American Society Of Hematology Dec. 5-8

GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that three abstracts including data from the Company's clinical and research portfolio have been accepted for oral presentations and two abstracts have been accepted for poster presentations at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually December 5-8, 2020.

Of particular note are primary and key secondary endpoint data from additional analysis of the Phase 3 RESET study evaluating the efficacy of rivipansel in VOC. These findings point to the potential benefits, clinical improvements and improved outcomes associated with early treatment with GlycoMimetics' wholly-owned product candidate, which include shorter hospital stays for patients and reduced need for IV opioids to treat pain.

A second presentation includes data from two different preclinical models of VOC using GlycoMimetics' highly potent and specific E-selectin antagonist, GMI-1687. This presentation will highlight the product candidate's potential for intravenous and subcutaneous administration to treat VOC by inhibiting occlusions and restoring blood flow.

A third presentation discloses how targeting E-selectin with uproleselan may help patients with AML overcome resistance to venetoclax combined with hypomethylating agent (HMA) based therapy.

Poster presentations convey how GMI-1359, a rationally-designed small molecule that inhibits E-selectin and CXCR4 (a chemokine receptor), enhances sorafenib's anti-leukemia effect in pre-clinical AML models; and how GMI-1359 can uniquely generate motility-enhancing signals in AML cells and deplete AML cells from protective vascular niches in the bone marrow.

"GlycoMimetics is honored to have five abstracts from across our product candidate portfolio selected for presentations at this year's ASH meeting. The data convey new insights into the critical role of E-selectin in both malignant and inflammatory, adhesion-mediated conditions, suggesting novel treatment options for unmet need in sickle cell disease and AML," said Helen Thackray, MD, FAAP, GlycoMimetics' Chief Medical Officer.

Details on GlycoMimetics presentations at the ASH Meeting are as follows:

Title: Restoration of Normal Blood Flow in Mouse Models of Sickle Cell Vaso-occlusion Following Intravenous or Subcutaneous Administration of a Highly Potent E-Selectin Specific Inhibitor.

Presenters: Madhan Thamilarasan, William E. Fogler, John L. Magnani and Rahima Zennadi.

Session: 113 Hemoglobinopathies, Excluding Thalassemia--New Genetic Approaches to Sickle Cell Disease: New Insights Into Sickle Cell Disease Pathophysiology.

Date and Time: December 5, 2020. 2:00 -- 3:30 p.m. EST

Presentation Time: 2:45 p.m.

Title: Targeting E-selectin with GMI-1271 Overcomes Microenvironment-mediated Resistance to Venetoclax/HMA Therapy.

Presenters: Kyung Hee Chang, Muharrem Muftuoglu, Weiguo Zhang, Mahesh Basyal, Lauren Ostermann, William E. Fogler, John L. Magnani and Michael Andreeff.

Session: 604 Molecular Pharmacology and Drug Resistance in Myeloid Diseases.

Date and Time: Saturday, December 5, 2020. 2:00 - 3:30 p.m.

Presentation Time: 3:15 p.m.

Title: Dual CXCR4 and E-selectin Inhibition (GMI-1359) Rapidly Increases AML Cellular Motility Prior to Intravasation and Vascular Niche Depletion Observed by Intravital Bone Marrow 2-Photon Microscopy.

Presenters: Tomasz Zal, M. Anna Zal, Mateusz Rytelewski, Kyung Hee Chang, Rodrigo Jacamo, William E. Fogler, John L. Magnani and Michael Andreeff.

Session: 616 Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II.

Date: Sunday, December 6, 2020.

Virtual Poster Hall: 7 a.m. -- 3:30 p.m.

Title: Combined Blockage of E-selectin and CXCR4 (GMI-1359) Enhances Anti-Leukemia Effect of FLT3 Inhibition (Sorafenib) and Protects Hematopoiesis in Pre-clinical AML Models.

Presenters: Weiguo Zhang, Kyung Hee Chang, Mahesh Basyal, Yannan Jia, Lauren Ostermann, William E. Fogler, John L. Magnani, M. Anna Zal, Tomasz Zal and Michael Andreeff.

Session: 616 Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III.

Date: Monday, December 7, 2020.

Virtual Poster Hall: 7 a.m. -- 3:30 p.m.

Title: Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis

Presenter: Helen Thackray

Session Name: 114 Hemoglobinopathies, Excluding Thalassemia--Clinical: Novel Treatments for Sickle Cell Disease

Date and Time: Monday, December 7, 2020. 1:30 - 3:00 p.m.

Presentation Time: 1:45 p.m.

The accepted abstracts are available online through the ASH meeting website, https://ash.confex.com/ash/2020/webprogram/start.html